Back to search results

Artemisia Annua for Small Intestinal Bacterial Overgrowth (SIBO)

This study is testing if a dietary supplement called Artecinua™ (made from Artemisia annua leaves) is safe and well-tolerated for adults with hydrogen-type Small Intestinal Bacterial Overgrowth (SIBO). SIBO can cause symptoms like bloating and stomach pain. Participants will take either Artecinua™ or a placebo (an inactive substance, in this case, alfalfa) for five weeks. The study will look at your blood counts, metabolic profile, and heart rate after five weeks to see how you respond. You may be able to join if you are an adult aged 18 or older, have an IBS-SSS score above 175, and meet specific criteria for hydrogen-type SIBO. The study aims to enroll 32 participants, but its current status is unclear.

Study design
This is a triple-blind, placebo-controlled study, meaning neither you, your doctor, nor the researchers will know if you are receiving Artecinua™ or the placebo. It aims to enroll up to 32 participants.
What's involved
You will take the study supplement for 5 weeks, plus an additional week to gradually increase the dose. You will also have two breath tests and three blood tests, requiring overnight fasting before each.
Compensation
Not stated in the trial record.
Follow-up
Your complete blood count, comprehensive metabolic profile, and heart rate will be measured at 5 weeks after starting the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06721884

Herbal Evaluation Of Artemisia Annua For Small Intestinal Bacterial Overgrowth

Recruiting
PHASE1Ages 18+Interventional
National University of Natural Medicine
~32 participants
Updated 2025-06-04 on ClinicalTrials.gov
What's tested:Artemisia Annua Leafplacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Complete blood count
Measured over 5 weeks
+9 more outcomes measured

Conditions

Small Intestinal Bacterial Overgrowth Syndrome (SIBO)

Explore related trials

Small intestinal bacterial overgrowth

NCT06721884

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Helfgott Research Institute - National University of Natural Medicine

    Portland, Oregonstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Joshua Z Goldenberg, ND
[email protected]
503-552-1555
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults 18 years of age or older
IBS-SSS score \>175
Meets North American Consensus criteria for H2 SIBO
Willing to take Artecinua™ or placebo as a dietary supplement for 5 weeks
Willing to have two lactulose breath tests and do the prep diet 24 hours before and fast overnight before the test
Willing to have three blood drawstests and fast overnight before the draw
Able to speak, read, and understand English
Able to provide informed consent
For individuals of child-bearing potential, willing to use an intrauterine device or two other concurrent forms of birth control to prevent pregnancy while enrolled

Exclusion

Use of antibiotic pharmaceuticals or supplements 14 days before baseline breath test
Initiation of change in diet, medication, or supplement regime within 30 days
Hospitalization within the past 3 months
Women who are breastfeeding, pregnant, or planning pregnancy in the next 4 months
Allergies to any of the ingredients in the study products.
Individuals with chronic kidney or liver disease, cancer, colorectal disease and/or other rare disorders that at the discretion of the PI or Clinical \*Investigator may impact their safety or confound trial results
The use of any high-risk medications with narrow therapeutic indices metabolized by CYP450 enzymes: Warfarin (CYP2C9), Tacrolimus/Cyclosporine (CYP3A4), Efavirenz (CYP2B6), and Codeine (CYP2D6).
Drugs requiring activation for efficacy: Clopidogrel (CYP2C19), Codeine (CYP2D6), and Tamoxifen (CYP2D6) (citations).
GFR: \<30 mL/min/1.73m²
Hepatitis from any cause.
Excessive alcohol use (\> seven drinks/week in women and \> fourteen in men).
Hepatic (ALT, AST, bilirubin) and renal (creatinine, estimated GFR) parameters outside of normal range at screening.

What this trial measures

  • Complete blood count5 weeks

    RBC, WBC, platelets

  • Comprehensive metabolic profile5 weeks

    eGFR, electrolytes, BUN:Cr, AST, ALT, GGT, alkaline phosphatase, bilirubin

  • Vital sign measurement (heart rate)5 weeks

    bpm

  • Vital sign measurement (blood pressure)5 weeks

    mmHg

  • Vital sign measurement (temperature)5 weeks

    degrees F

  • Vital sign measurement (weight)5 weeks

    kg

  • Vital sign measurement (height)5 weeks

    meters

  • Vital sign measurement (body mass index)5 weeks

    weight (kg) / \[height (m)\]²

  • Adverse event monitoring5 weeks

    Adverse events

  • Quality of life5 weeks

    IBS-QoL